0.600
0.000
(0.00%)
May 23 - Close
OTCMKTS
data delayed by 15 mins -
Disclaimer
Currency in USD
| Range | - |
| 52 week | 0.55 - 5.25 |
| Open | - |
| Vol / Avg. | 0.00/3,459.00 |
| Mkt cap | 1.48M |
| P/E | - |
| Div/yield | - |
| EPS | -11.24 |
| Shares | 2.47M |
| Beta | 1.93 |
| Inst. own | 41% |
Events
Mar 25, 2013
Q4 2012 Tengion, Inc. Earnings Release
|
|
Key stats and ratios
| Q3 (Sep '12) | 2011 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -368.16% | -90.85% |
| Return on average equity | - | -237.15% |
| Employees | 33 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite G 3929 Westpoint Blvd.,, Winston-Salem
EAST NORRITON, PA 27103
United States - Map
+1-336-7225855 (Phone)
+1-302-6555049 (Fax)
EAST NORRITON, PA 27103
United States - Map
+1-336-7225855 (Phone)
+1-302-6555049 (Fax)
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
Develops artificial organs and tissue. The Company develops bioengineered organs and tissues based on experiments on autologous tissue engineering technology and optimal biomaterials. Tengion's technology of creating a neo-organ, such as the Tengion Neo-Bladder, starts when a surgeon sends the patient's biopsy to Tengion.
Officers and directors
| David I. Scheer | Independent Chairman of the Board | |
| Timothy Bertram PhD | President - Research and Development, Chief Scientific Officer | |
| John L. Miclot | President, Chief Executive Officer, Director | |
| A. Brian Davis | Chief Financial Officer, Vice President - Finance | |
| Carl-Johan Dalsgaard M.D. | Independent Director | |
| Diane K. Jorkasky M.D. | Independent Director | |
| Richard E Kuntz MD | Independent Director | |
| Lorin Jeffry Randall | Independent Director |